Sermorelin vs Tesamorelin: Research Protocol Comparison
Primary Mechanism Direct GHRH receptor agonism → pulsatile GH release from anterior pituitary Modified GHRH analog with enhanced receptor affinity + tissue-specific lipolytic signaling Tesamorelin's structural modification creates dual-action profile sermoreli
This comparison does not assign a generated winner or score.
- Primary Mechanism
- Direct GHRH receptor agonism → pulsatile GH release from anterior pituitary
- Modified GHRH analog with enhanced receptor affinity + tissue-specific lipolytic signaling
- Tesamorelin's structural modification creates dual-action profile sermorelin lacks
- Plasma Half-Life
- 10–20 minutes (rapid DPP-IV degradation)
- 26–38 minutes (hexenoic acid protects N-terminus)
- Longer half-life allows less frequent dosing and sustained GH elevation
- Visceral Fat Reduction
- Minimal to none in controlled trials
- 15–20% reduction in CT-measured VAT over 26 weeks
- Only tesamorelin demonstrates consistent, significant visceral adipose loss
- IGF-1 Elevation
- 40–60% increase from baseline at therapeutic dose
- 80–120 ng/mL absolute increase, dose-dependent
- Both effective; tesamorelin produces higher sustained IGF-1 levels
- FDA Status
- Approved for diagnostic GH testing only
- Approved for HIV-associated lipodystrophy (2010)
- Tesamorelin has formal regulatory pathway for body composition indication
- Typical Research Dose
- 1–2 mcg/kg SC daily, typically before sleep
- 2 mg SC daily, administered in morning
- Sermorelin dosed by weight; tesamorelin uses fixed milligram dose
- Storage Stability
- Lyophilized: −20°C; reconstituted: 2–8°C, use within 14 days
- Lyophilized: −20°C; reconstituted: 2–8°C, use within 28 days
- Tesamorelin's modification confers modest stability advantage post-reconstitution
- Cost (Research Grade)
- $180–$320 per 5 mg vial depending on purity certification
- $280–$450 per 2 mg vial (higher synthesis complexity)
- Sermorelin offers better cost-per-dose for non-adipose research applications